vs
C4 Therapeutics, Inc.（CCCC）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
C4 Therapeutics, Inc.的季度营收约是Protalix BioTherapeutics, Inc.的1.2倍（$11.0M vs $9.1M），Protalix BioTherapeutics, Inc.净利率更高（-60.3% vs -186.0%，领先125.6%），C4 Therapeutics, Inc.同比增速更快（112.8% vs -49.9%），过去两年C4 Therapeutics, Inc.的营收复合增速更高（90.4% vs -6.7%）
C4 Therapeutics是一家临床阶段生物制药企业，专注于开发靶向蛋白降解疗法，用于治疗癌症及其他存在重大未满足医疗需求的严重疾病。公司依托自有专利TORPEDO平台设计小分子降解剂清除致病蛋白，目前拥有多条肿瘤领域研发管线，并与头部制药企业达成战略合作。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
CCCC vs PLX — 直观对比
营收规模更大
CCCC
是对方的1.2倍
$9.1M
营收增速更快
CCCC
高出162.7%
-49.9%
净利率更高
PLX
高出125.6%
-186.0%
两年增速更快
CCCC
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $11.0M | $9.1M |
| 净利润 | $-20.5M | $-5.5M |
| 毛利率 | — | 49.4% |
| 营业利润率 | -210.1% | -51.1% |
| 净利率 | -186.0% | -60.3% |
| 营收同比 | 112.8% | -49.9% |
| 净利润同比 | 40.7% | -184.8% |
| 每股收益（稀释后） | $-0.09 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCCCPLX
| Q4 25 | $11.0M | $9.1M | ||
| Q3 25 | $11.2M | $17.9M | ||
| Q2 25 | $6.5M | $15.7M | ||
| Q1 25 | $7.2M | $10.1M | ||
| Q4 24 | $5.2M | $18.2M | ||
| Q3 24 | $15.4M | $18.0M | ||
| Q2 24 | $12.0M | $13.5M | ||
| Q1 24 | $3.0M | — |
净利润CCCCPLX
| Q4 25 | $-20.5M | $-5.5M | ||
| Q3 25 | $-32.2M | $2.4M | ||
| Q2 25 | $-26.0M | $164.0K | ||
| Q1 25 | $-26.3M | $-3.6M | ||
| Q4 24 | $-34.6M | $6.5M | ||
| Q3 24 | $-24.7M | $3.2M | ||
| Q2 24 | $-17.7M | $-2.2M | ||
| Q1 24 | $-28.4M | — |
毛利率CCCCPLX
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
营业利润率CCCCPLX
| Q4 25 | -210.1% | -51.1% | ||
| Q3 25 | -306.4% | 11.9% | ||
| Q2 25 | -441.0% | 7.5% | ||
| Q1 25 | -402.9% | -41.0% | ||
| Q4 24 | -728.4% | 39.6% | ||
| Q3 24 | -183.9% | 22.2% | ||
| Q2 24 | -178.6% | -18.0% | ||
| Q1 24 | -1060.2% | — |
净利率CCCCPLX
| Q4 25 | -186.0% | -60.3% | ||
| Q3 25 | -286.4% | 13.2% | ||
| Q2 25 | -402.6% | 1.0% | ||
| Q1 25 | -363.7% | -35.8% | ||
| Q4 24 | -667.8% | 35.6% | ||
| Q3 24 | -160.6% | 18.0% | ||
| Q2 24 | -147.6% | -16.4% | ||
| Q1 24 | -933.2% | — |
每股收益（稀释后）CCCCPLX
| Q4 25 | $-0.09 | $-0.06 | ||
| Q3 25 | $-0.44 | $0.03 | ||
| Q2 25 | $-0.37 | $0.00 | ||
| Q1 25 | $-0.37 | $-0.05 | ||
| Q4 24 | $-0.50 | $0.10 | ||
| Q3 24 | $-0.35 | $0.03 | ||
| Q2 24 | $-0.26 | $-0.03 | ||
| Q1 24 | $-0.41 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.6M | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $256.6M | $48.2M |
| 总资产 | $359.1M | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CCCCPLX
| Q4 25 | $74.6M | $14.7M | ||
| Q3 25 | $58.8M | $13.6M | ||
| Q2 25 | $78.2M | $17.9M | ||
| Q1 25 | $51.3M | $19.5M | ||
| Q4 24 | $55.5M | $19.8M | ||
| Q3 24 | $59.6M | $27.4M | ||
| Q2 24 | $73.1M | $23.4M | ||
| Q1 24 | $89.7M | — |
股东权益CCCCPLX
| Q4 25 | $256.6M | $48.2M | ||
| Q3 25 | $154.4M | $52.9M | ||
| Q2 25 | $174.1M | $49.9M | ||
| Q1 25 | $195.1M | $45.2M | ||
| Q4 24 | $216.0M | $43.2M | ||
| Q3 24 | $242.7M | $32.4M | ||
| Q2 24 | $247.1M | $28.6M | ||
| Q1 24 | $258.3M | — |
总资产CCCCPLX
| Q4 25 | $359.1M | $82.3M | ||
| Q3 25 | $265.5M | $82.3M | ||
| Q2 25 | $296.5M | $78.5M | ||
| Q1 25 | $319.5M | $73.9M | ||
| Q4 24 | $349.6M | $73.4M | ||
| Q3 24 | $376.1M | $61.6M | ||
| Q2 24 | $381.1M | $91.5M | ||
| Q1 24 | $398.4M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.1M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | — | $1.6M |
| 自由现金流率自由现金流/营收 | — | 17.8% |
| 资本支出强度资本支出/营收 | — | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
经营现金流CCCCPLX
| Q4 25 | $-22.1M | $2.0M | ||
| Q3 25 | $-31.2M | $-3.7M | ||
| Q2 25 | $-12.1M | $-5.2M | ||
| Q1 25 | $-33.3M | $-5.1M | ||
| Q4 24 | $-17.9M | $4.0M | ||
| Q3 24 | $-24.1M | $4.1M | ||
| Q2 24 | $-5.0M | $-3.6M | ||
| Q1 24 | $-18.1M | — |
自由现金流CCCCPLX
| Q4 25 | — | $1.6M | ||
| Q3 25 | $-31.6M | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | $-17.9M | $3.6M | ||
| Q3 24 | $-24.1M | $4.0M | ||
| Q2 24 | $-5.2M | $-3.8M | ||
| Q1 24 | — | — |
自由现金流率CCCCPLX
| Q4 25 | — | 17.8% | ||
| Q3 25 | -281.5% | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | -346.5% | 19.6% | ||
| Q3 24 | -157.2% | 22.4% | ||
| Q2 24 | -43.1% | -28.1% | ||
| Q1 24 | — | — |
资本支出强度CCCCPLX
| Q4 25 | — | 4.4% | ||
| Q3 25 | 3.7% | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | 0.1% | 2.3% | ||
| Q3 24 | 0.1% | 0.5% | ||
| Q2 24 | 1.6% | 1.3% | ||
| Q1 24 | 0.0% | — |
现金转化率CCCCPLX
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCCC
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
